As Indiana enters 2026, a major shift in the healthcare landscape is promising to make high-demand weight-loss medications more accessible to millions. With the launch of the TrumpRx initiative, drugs like Wegovy, Ozempic, Mounjaro, and Zepbound are set for significant price cuts and expanded coverage.
To help Hoosiers navigate these changes, local physician and obesity-medicine expert Dr. Rickin Shah, co-owner of Pure Regenerative Medicine, joined us to break down what this means for a state where nearly 38% of adults are living with obesity.
What is TrumpRx?…